European Archives - Page 632 of 1003 - European Medical Journal

Improving Cardiovascular Outcomes for Rheumatoid Arthritis Patients

ATHEROSCLEROSIS rates were reduced in patients with rheumatoid arthritis as a result of adopting a treat-to-target approach compared with a traditional…

EMJ Dermatology 6 [Suppl 2] 2019

This presentation by Dr Weisenseel considered the role of fumaric acid esters (FAE) in plaque psoriasis. FAE, first developed in 1959 and approved in 1994..

Dimethyl Fumarate in Psoriasis Therapy

This presentation by Dr Weisenseel considered the role of fumaric acid esters (FAE) in plaque psoriasis.

Patient engagement is now essential, not only in order to develop new drugs but also to provide insights for medicines that are already approved and on the market

Pol Vandenbroucke holds the position of Chief Medical Officer for Pfizer’s recently established Hospital Business Unit, a position he was promoted to at the start of 2019. We spoke to Vandenbroucke about how he applies his 30+ years of industry experience to his role today, and Medical Affairs’ evolving role in the development of medicines, ahead of his upcoming speech at eyeforpharma, Barcelona, 2019.

Macrophages: A potential new target for reducing hypertension?

HYPERTENSION is a global health problem with a number of modifiable risk factors; stress, diet, and activity levels are all known to play a part in the…

Atherosclerosis risk linked to poor sleep quality

THE IMPORTANCE of a good night’s sleep on health is not a new topic, but researchers in Europe and the USA have recently added to this growing evidence…

Top selling biologics to come off patent

There are a number of biologic medicines that have come off patent or are due to come off patent in the next few years. Learn more about the intricacies of the biologics market in this infographic.

"We need to move from the idea people have today – that digital just enables you to do things slightly better – to looking at the potential of doing completely new things"

Ameet Nathwani is Chief Medical Officer and Executive Vice President at Sanofi. As a person well known for his interest and work in the use of new technologies in healthcare, he spoke to us about the changes these innovations are making to the pharmaceutical industry and the potential they have to transform the way patients are treated in the future.

The Gut and Cow’s Milk Allergy

MICROBES in the gut may offer the potential to prevent cow’s milk allergy from developing in infants…

Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade

The rising incidence of CSCC presents a major challenge for healthcare systems and the frequency and impact of progression to advanced disease is…